In 310 patients with MDM2-amplified advanced dedifferentiated liposarcoma, first-line brigimadlin did not significantly improve median PFS vs doxorubicin (8.4 vs 7.2 months; HR 0.79, P=0.096); response rate 22.3% vs 8.6%, with frequent grade ≥3 neutropenia.
RCTn = 310
Schöffski et al. Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial